Intriguingly, single-cell RNA sequencing and immunohistochemical analyses revealed higher FOXM1 expression in pancreatic cancer metastases than in primary tumors.<h4>Conclusion</h4>Overall, these findings suggest that targeting FOXM1 may be a promising therapeutic strategy to interfere with the metastatic progression of pancreatic cancer, which might particularly benefit patients with high blood platelet counts. The gene discussed is FOXM1; the disease is familial pancreatic carcinoma.